Table 2.
Patient disease-specific characteristics and medications
| HFrEF | |
|---|---|
| Disease-specific characteristics | |
| Left ventricular ejection fraction (%) | 29 ± 8 |
| Left ventricular end-diastolic diameter (cm) | 6.4 ± 1.1 |
| Left ventricular end-systolic diameter (cm) | 5.6 ± 1.4 |
| Left ventricular fractional shortening (%) | 13 ± 8 |
| B-type natriuretic peptide (pg/mL) | 138 ± 122 |
| Diagnosis | |
| Ischemic cardiomyopathy | 4 / 9 |
| Non-ischemic cardiomyopathy | 5 / 9 |
| NYHA class II | 7 / 9 |
| NYHA class III | 2 / 9 |
| Type 2 diabetes | 2 / 9 |
| Coronary artery disease | 6 / 9 |
| Medications | |
| β-blocker | 8 / 9 |
| Angiotensin-converting enzyme inhibitor | 7 / 9 |
| Angiotensin receptor inhibitor | 2 / 9 |
| Statin | 8 / 9 |
| Diuretic | 8 / 9 |
| Aldosterone antagonist | 9 / 9 |
| Anticoagulant | 3 / 9 |
| Metformin | 2 / 9 |
Data are mean ± SD or number of all cases (n = 9). HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association.